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Abstract
Background: Our objective was to evaluate and compare the effect of abacavir on levels of biomarkers associated
with cardiovascular risk.
Methods: In an open-label randomized trial, HIV-infected patients were randomized 1:1 to switch from zidovudine/
lamivudine to abacavir/lamivudine or tenofovir/emtricitabine. In the present analysis, we measured levels of
interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble intercellular adhesion molecule-1 (sICAM-1),
soluble vascular adhesion molecule-1 (sVCAM-1), E-selectin, and myeloperoxidase (MPO) at baseline and 4, 12, and
48 weeks after randomization. D-dimer and fasting lipids were measured at baseline and weeks 12 and 48. Levels
of biomarkers at all time points and changes from baseline were compared across study arms using Wilcoxon rank
sum test.
Results: Of 40 included patients, 35 completed 48 weeks of randomized therapy and follow up. Levels of E-selectin
(P = 0.004) and sVCAM-1 (P = 0.041) increased transiently from baseline to week 4 in the abacavir arm compared
with the tenofovir arm, but no long-term increases were detected. We found no significant differences between
study arms in the levels or changes in the levels of sICAM-1, MPO, d-dimer, IL-6, or hs-CRP. Levels of total
cholesterol and high density lipoprotein (HDL) increased in the abacavir arm relative to the tenofovir arm, but no
difference was found in total cholesterol/HDL ratio.
Conclusion: In patients randomized to abacavir-based HIV-treatment transient increases were seen in the plasma
levels of E-selectin and sVCAM-1 compared with treatment with tenofovir, but no difference between study arms
was found in other biomarkers associated with endothelial dysfunction, inflammation, or coagulation. The clinical
significance of these findings is uncertain.
Trial Regestration: Clinicaltrials.gov identifier: NCT00647244.
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Background
The association between abacavir (ABC) use and myo-
cardial infarction (MI) has been heavily debated since
the Data Collection on Adverse Events of Anti-HIV
Drugs (DAD) Study Group reported an increased risk of
MI in patients with current or recent ABC use [1]. Data
from other cohort studies have provided conflicting
results [2-7], whereas analyses from clinical trials gener-
ally do not lend support to a causal relationship between
ABC and MI [8-11]. In brief, the association between
ABC and risk of MI was also found in a Danish cohort
study [4] and in the SMART study dataset [7]. On the
o t h e rh a n dd a t af r o mh i g h l ya c t i v ea n t i - r e t r o v i r a lt h e r -
apy (HAART) naïve patients in pooled GSK-sponsored
trials [6], the AIDS Clinical Trial Group (ACTG) A5001
[2], the Veterans Health Administration’sC l i n i c a lC a s e
Registry [3], and a case-control study from The French
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association between ABC and MI.
In stronger evidence level data from several rando-
m i z e dc o n t r o l l e dt r i a l s( R C T s )c o m p a r i n gA B Cw i t h
tenofovir disoproxil fumarate (TDF), no increase in rate
of MI was detected among patients randomized to
ABC-based compared to TDF-based therapy [9-11].
Only in the STEAL-study, in which patients assigned to
the ABC arm had a higher prevalence of cardiovascular
risk factors, was an increased rate of cardiovascular
events with ABC use detected [8]. Most recently, in a
trial level meta-analysis of RCTs in which ABC was ran-
domized as part of a HAART regimen, no association
between increased risk of MI and ABC was found [12].
However, of the RCTs mentioned above, only two
have comprised patients with suppressed HIV-infection
[8,9]. A feature of uncontrolled HIV replication is ele-
vated levels of inflammatory markers that are associated
with an increased risk of cardiovascular events [13-15],
but initiation of HAART in treatment-naïve patients
reduces the levels of these biomarkers [11]. Thus, some
of the discrepancy between studies may have been
caused by the confounding noise of uncontrolled HIV
replication among HAART-naïve patients. Investigations
of inflammatory biomarkers have not provided consis-
tent evidence for increased coagulation, inflammation,
or endothelial dysfunction during ABC treatment
[7,11,16-20], but most studies have been limited by a
lack of randomization and HLAB5701-screening, or
included patients with uncontrolled HIV replication.
The Efficacy and Safety of Switching from Zidovudine
to Tenofovir or Abacavir in HIV-infected Patients
(SWAP) study was a randomized trial comparing
switching from zidovudine (AZT) to ABC or TDF with
parameters of renal function and bone metabolism as
the pre-specified primary endpoints. However, the study
provided an opportunity to perform a post hoc analysis
to investigate biomarkers of cardiovascular risk as early
as 4 weeks after treatment switch in patients with sup-
pressed HIV-infection who were randomized to ABC or
T D Ft r e a t m e n t .W er e p o r th e r eo nt h ef i n d i n g sf r o m
the analyses of these cardiovascular biomarkers.
Methods
Patients
The SWAP study was an open-label, parallel-group, ran-
domized clinical trial assessing the safety and efficacy of
switching from AZT to ABC- or TDF-based therapy.
Eligible patients had documented HIV-infection and, for
at least 3 months, had been treated with HAART com-
prising AZT and had undetectable plasma HIV-RNA. A
sample size of 90 participants was estimated as being
required to detect differences in the primary outcome
measures at a 5% significance level. Patients who had
previously used ABC or TDF, had diabetes mellitus,
untreated hypertension, or who were positive for the
HLAB5701 allele upon screening were excluded.
Informed consent was obtained before enrolment. At
baseline, patients were stratified after use of protease
inhibitors and randomized 1:1 to switch from AZT to
ABC 600 mg or TDF 300 mg daily. If lamivudine (3TC)
or emtricitabine (FTC) was given as part of HAART at
inclusion, patients were randomized to a fixed-dose
treatment with ABC/3TC 600/300 mg or TDF/FTC
300/200 mg daily. The study took place at the Depart-
ment of Infectious Diseases, Aarhus University Hospital,
Skejby, Denmark. Patients were followed up at 4, 8, 12,
24, and 48 weeks after randomization. A pre-planned
follow up at 96 weeks was not performed because the
study was discontinued in November 2009. The pre-spe-
cified primary endpoints were parameters of renal func-
tion, bone metabolism and bone mass density,
lipodystrophy, and insulin resistance. Analysis of cardio-
vascular biomarkers was a sub-study that was added as
an amendment when the suspicion of increased cardio-
vascular risk with ABC treatment was raised, but collec-
tion of plasma samples was part of the original protocol
and did not require further selection of study subjects.
Both the main and sub-study was approved by the
Regional Research Ethics Committee, Central Denmark
Region (Journal number: M-20070189; Eudract. number:
2007-004372-39) and conducted in accordance with
Good Clinical Practice.D a t ao nf a s t i n gl i p i d s ,f a s t i n g
glucose, anthropometric information, age, sex, smoking
habits, blood pressure, CD4+ cell counts, viral load, and
duration of HIV-infection and HAART exposure were
retrieved from the study database or patient records.
Based on relevant data, Framingham score and esti-
mated 10-year risk of cardiovascular events were calcu-
lated as described previously [21].
Measurement of biomarkers
Plasma samples (EDTA- and citrate-treated) were stored
at -80°C until analysis. To detect both early and late
changes in inflammation and endothelial dysfunction
markers, we analyzed levels of IL-6, high sensitivity (hs)-
CRP, soluble intercellular adhesion molecule-1 (sICAM-
1), soluble vascular adhesion molecule-1 (sVCAM-1), E-
selectin, and myeloperoxidase (MPO) at baseline and at
weeks 4, 12, and 48 after randomization in plasma.
Citrate plasma was not collected at week 4 and, there-
fore, d-dimer levels were only measured at baseline and
w e e k s1 2a n d4 8 .E - s e l e c t i n ,M P O ,s I C A M - 1 ,a n d
sVCAM-1 were measured in a multiplex assay on the
Luminex platform as described by the manufacturer
(Milliplex CVD Panel 1, Millipore, Copenhagen, Den-
mark). Inter- and intra-assay coefficient of variation
(CV) ranged from 8.5-16.3% and 4.5-12.3%, respectively;
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Page 2 of 10lower limits of detection are 79 pg/mL for E-selectin, 16
pg/mL for sVCAM-1, 9 pg/mL for sICAM-1, and 7 pg/
mL for MPO. Commercially available ELISA-based
assays were used to determine levels of IL-6 (Invitrogen,
CA, USA; intra-assay CV 4.71-8.33%, inter-assay CV
6.70-10.0%) and d-dimer (American Diagnostica Inc.,
CT, USA; intra-assay CV < 10%). The lower limits of
detection were 4 μg/L for d-dimer and 0.104 pg/mL for
IL-6. Hs-CRP levels were analyzed with a high-sensitiv-
i t yi n - h o u s es a n d w i c hE L I S Aw i t hal o w e rd e t e c t i o n
limit of 0.2 mg/L. All measurements were performed in
duplicate. Samples with undetectable levels were
assigned the value of the lower detection limit.
Statistics
Baseline data were compared using c
2-test for categori-
cal variables and two sample t-test or Wilcoxon rank
sum test for continuous variables, depending on a
skewed or Gaussian distribution of data, which was
assessed through visual inspection of frequency histo-
grams and normal probability plots. Median levels of
biomarkers at baseline and at weeks 4, 12, and 48, as
well as relative changes from baseline to weeks 4, 12,
and 48 were compared across the 2 study arms by Wil-
coxon rank sum test. Because the prognostic signifi-
cance of hs-CRP for cardiovascular events is well
established [22] and levels >1 mg/L predict for higher
risk of adverse cardiovascular events [23], we compared
the proportion of patients in each arm with hs-CRP > 1
mg/L at all time points by c
2-test in a post hoc analysis.
Median levels of fasting lipids at baseline, week 12, and
week 48, as well as relative changes from baseline to
weeks 12 and 48, respectively, were compared between
the 2 study arms by Wilcoxon rank sum test. Stata 10
was used for statistical analyses. P-values < 0.05 were
considered statistically significant.
Results
Study group
Because of uncertainty about ABC as a first-line treat-
ment option, patient inclusion was suspended in Janu-
ary 2009 to await further confirmation on this issue.
The study was finally terminated in August 2009. The
flow of patient inclusion and follow-up is illustrated in
Figure 1.
Forty patients were enrolled during the period June to
December 2008, with 20 in each study arm. Two
patients in the ABC/3TC arm were excluded shortly
after randomization and contribute only to baseline
data. One patient was excluded because of an allergic
skin reaction upon starting ABC therapy (the patient
was tested negative for the HLAB5701 allele), and one
patient was excluded because of alcohol abuse and poor
adherence to study drugs. Three patients in the ABC/
3TC arm were excluded at week 12 for the following
reasons: initiated treatment for hepatitis C, intention of
pregnancy, and a history of diabetes mellitus, respec-
tively. The latter patient had a history of diabetes prior
to randomization and was listed as a screening failure.
All 3 patients contributed data up to and including
week 12. The remaining 35 study subjects all completed
48 weeks of therapy. One patient (TDF/FTC arm) did
not provide the week-4 blood sample. One serious
adverse event was reported during the study; this was a
resolved episode of pyelonephritis in a patient with a
history of recurrent urinary tract infections. Five grade 2
adverse advents were registered (4 in the ABC/3TC arm
and 1 in the TDF/FTC arm), but none necessitated dis-
continuation of study drugs. No grade 3 or 4 adverse
advents were reported.
Baseline characteristics of the patients are shown in
Table 1. All patients received zidovudine (AZT) in com-
bination with 3TC at inclusion, and were randomized to
either ABC/3TC or TDF/FTC. The proportion of smo-
kers and males was higher and duration of HAART
exposure longer in the TDF/FTC arm. Patients in both
arms were virologically suppressed throughout the
study.
Cardiovascular biomarkers
The median levels of cardiovascular biomarkers at
baseline and at weeks 4, 12, and 48 are shown in Fig-
ure 2. Relative changes from baseline to weeks 4, 12,
and 48, respectively, are shown in Table 2. Levels of E-
selectin were higher at baseline among patients in the
TDF/FTC arm compared with the ABC/3TC arm (P =
0.014), but this difference levelled out at week 4 and
did not reoccur at subsequent time points. Corre-
spondingly, changes in levels of E-selectin from base-
line to week 4 were significantly higher in the ABC/
3TC arm compared with the TDF/FTC arm (P =
0.004). A similar pattern was observed with levels of
sVCAM-1, which increased from baseline to week 4 in
the ABC/3TC arm compared with the TDF/FTC arm
(P = 0.041). For both markers, the increase was transi-
ent, and no significant changes in the level of E-selec-
tin or sVAM-1 were detected from baseline to week 12
or 48, respectively. We performed analyses stratified
for sex and age to examine whether the changes in E-
selectin and sVCAM1 from baseline to week 4 could
have been influenced by these variables, but we did
n o tf i n da n yi n d i c a t i o n sh e r e o f .
We observed no significant differences in the level of
sICAM-1, MPO, d-dimer, IL-6, or hs-CRP between
study arms at any time point. Also, changes in the level
of sICAM-1, MPO, d-dimer, IL-6, or hs-CRP from base-
line to weeks 4, 12, and 48, respectively, were not signif-
icantly different between study arms.
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Page 3 of 10Levels of hs-CRP increased modestly in the ABC/3TC
arm compared with the TDF/FTC the arm, but the
change was below the level of significance. Accordingly,
the proportion of patients with hs-CRP > 1 mg/L in the
TDF/FTC arm decreased from baseline to week 12 and
remained stable thereafter, whereas the opposite was
true for the ABC/3TC arm, but the difference was non-
significant (Figure 3).
Fasting lipids
Median levels of fasting lipids at baseline and at weeks
12 and 48 are shown in Figure 2. Relative changes from
baseline to weeks 12 and 48, respectively, are shown in
Table 2. At baseline, there was a trend towards higher
total cholesterol in the ABC/3TC arm compared with
the TDF/FTC arm. This difference became statistically
significant at subsequent time points and, accordingly,
we detected significant increases in total cholesterol
with ABC/3TC treatment compared with TDF/FTC
treatment (P =0 . 0 2 0a n dP = 0.002 for relative changes
at week 12 and 48, respectively). However, levels of
high-density lipoprotein (HDL) also increased in the
ABC/3TC arm compared with the TDF/FTC arm, and
reached statistical significance by week 48 (P = 0.002 for
relative change). Consequently, no difference in the total
cholesterol/HDL ratio was found between study arms.
Levels of low-density lipoprotein (LDL) were lower in
the TDF/FTC arm throughout the study, but the differ-
ence between the two groups was only significant at 48
weeks. There was no difference between study arms
with respect to the relative changes in LDL levels.
Discussion
In this sub-study of the SWAP randomized clinical trial,
the introduction of fixed-dose treatment with ABC/3TC
lead to increases in plasma levels of E-selectin and
sVCAM-1 compared with fixed-dose treatment with
TDF/FTC, but the effect was short term and could not
be detected after 12 and 48 weeks of follow up. No sig-
nificant changes in the levels of sICAM-1, MPO, hs-
CRP, or d-dimer were found.
As observed in previous randomized trials [8-10], we
detected an increase in the level of total cholesterol and
HDL in the ABC/3TC arm relative to the TDF/FTC
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Figure 1 Flow chart of inclusion and follow up. No figure legends.
Rasmussen et al. BMC Infectious Diseases 2011, 11:267
http://www.biomedcentral.com/1471-2334/11/267
Page 4 of 10arm, but there was no difference between total choles-
terol/HDL ratios. It is therefore likely that the observed
movement in fasting lipids will not significantly affect
the 10-year cardiovascular risk, in line with what was
seen in the STEAL study [8].
The strength of this study is its randomized design
and that no further selection of participants was neces-
sary, eliminating major sources of bias and confounding.
Furthermore, the entry criteria required that patients be
negative for the HLAB5701 allele, had not previously
been exposed to ABC or TDF, and had been virologi-
cally suppressed for at least 3 months prior to
randomization.
Other longitudinal studies did not find consistent pat-
terns of increasing levels of cardiovascular biomarkers
with ABC treatment. In a post hoc exploratory analysis
of the HEAT study, changes in levels of CRP, sVCAM-
1, and sICAM-1 were not significantly different among
patients randomized to ABC/3TC or TDF/FTC [11]. It
is noteworthy that participants in the HEAT study were
HAART naïve at randomization and may not be com-
parable to the virologically suppressed patients in our
study owing to the effect of uncontrolled HIV-replica-
tion on biomarker levels. The same applies for a
recently published non-randomized study among vire-
mic patients initiating abacavir or tenofovir, where no
difference in changes of cardiovascular biomarkers,
including early 4-weeks measurements, between treat-
ment groups was found [24]. Similarly, a sub-study of
the BIOCOMBO trial did not detect differences in mar-
kers of inflammation, endothelial dysfunction, hypercoa-
gulability, or insulin resistance after treatment was
switched to an ABC/3TC- or TDF/FTC-based regimen
[18]. The STEAL study is particularly interesting
because patients who switched to treatment with ABC/
3TC, as compared to TDF/FTC, had a higher rate of
cardiovascular events during follow up, but also a higher
proportion of smokers and higher Framingham scores at
baseline [8]. Nevertheless, an exploratory analysis did
not show any consistent association between ABC/3TC
and circulating levels of cardiovascular or inflammatory
biomarkers, although a trend towards higher ICAM-1
levels in the ABC/3TC arm was observed [20].
ICAM-1 is the endothelial ligand for macrophage-1
antigen (Mac-1) that is expressed on the surface of leu-
kocytes and mononuclear cells. Accumulation of these
cells in the vessel wall is a hallmark of atherosclerosis
and acute coronary syndrome, and is mediated by the
interaction between adhesion molecules on endothelial
and circulating cells. In an experimental system, Pablo
et al. recently demonstrated that ABC but not AZT or
3TC induced significant and dose-dependent increases
in rolling flux and adhesion in the leukocyte-endothe-
lium interaction [25]; these effects were blocked by
Table 1 Baseline characteristics
Parameter ABC/3TC (n = 20) TDF/FTC (n = 20)
Mean age (SD), years 50 (11.9) 46 (8.7)
Male sex, n (%) 11 (55.0) 14 (70.0)
Active smokers, n (%) 6 (30.0) 9 (45.0)
Mean weight (SD), kg 73.2 (12.1) 74.9 (16.3)
Mean BMI (SD), kg/m
2 25.2 (2.1) 25.0 (4.3)
Mean systolic blood pressure (SD), mmHg 133 (21.9) 135 (15.1)
Mean diastolic blood pressure (SD), mmHg 85 (10.9) 84 (9.4)
Median total cholesterol (IQR), mmol/L 5.7 (5.3-6.7) 5.35 (4.8-6.0)
Median LDL cholesterol (IQR), mmol/L 3.8 (3.1-4.3) 3.2 (2.6-4.0)
Median HDL cholesterol (IQR), mmol/L 1.3 (1.1-1.9) 1.2 (1.0-1.7)
Median triglyceride (IQR), mmol/L 1.5 (1.2-2.0) 1.4 (1.0-2.0)
Mean fasting plasma glucose (SD), mmol/L 5.4 (0.52) 5.4 (0.38)
Zidovudine/lamivudine at baseline, n (%) 20 (100) 20 (100)
PI at baseline, n (%) 6 (30.0) 6 (30.0)
Efavirenz at baseline, n (%) 11 (55.0) 9 (45.0)
Nevirapine at baseline, n (%) 3 (15.0) 5 (25.0)
Mean CD4+ cell count (SD), cells/mm
2, 567 (256) 540 (206)
Median duration of HAART exposure (IQR), months 86.5 (54.5-125) 106.5 (50.5-130)
Median time since HIV-diagnosis (IQR), months 127 (96.5-140.5) 122 (89-179)
Median Framingham score (IQR) 3 (0-6) 4 (1-7)
Median estimated 10-year cardiovascular risk a.m. Framingham (IQR), % 7 (3-10) 6 (3-11)
BMI = body mass index; PI = protease inhibitor; HAART = highly active antiretroviral therapy; HIV = human immunodeficiency virus.
Normally distributed data are presented as means with standard deviation (SD) in parenthesis. Skewed data are presented as medians with interquartile range
(IQR) in parenthesis.
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Page 5 of 10antibodies against ICAM-1 or Mac-1. Furthermore,
treatment of neutrophils and monocytes with ABC
increased the expression of Mac-1, whereas no increases
in ICAM-1, VCAM-1, or E-selectin were seen following
the treatment of endothelial cells [25]. Altogether, these
results suggest that ABC treatment could be linked to
increased expression of Mac-1 rather than endothelial
adhesion molecules, which would explain the paucity of
positive results in studies of the latter.
We found a transient effect of abacavir treatment on
some, but not all of the investigated cardiovascular bio-
markers. The main contribution of our analysis is the
early evaluation of these at week 4; in other randomized
trials such assessment was not done until week 12 [20]
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Figure 2 Median levels of cardiovascular biomarkers and fasting lipids during study treatment according to study arm. Hs-CRP = high
sensitivity C-reactive protein; IL-6 = interleukin 6; sVCAM-1 = soluble vascular adhesion molecule-1; slCAM-1 = soluble intercellular adhesion
molecule-1; MPO = myeloperoxidase; LDL = low density lipoprotein; HDL = high density lipoprotein. Whiskers indicate interquartile ranges. *P<
0.05 for ABC/3TC compared with TDF/FTC arm at the specific time point using Wilcoxon rank sum test.
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Page 6 of 10or 48 [11,18]. However, whether a temporary increase in
E-selectin and sVCAM-1 may translate into an increased
risk of myocardial infarction within such a short time
frame seems unlikely, and the clinical significance of
this finding, if any, is uncertain. In addition, for both E-
selectin and sVCAM-1, baseline levels were higher in
the TDF/FTC arm than in the ABC/3TC arm, though
only significantly so for E-selectin. Hence, we cannot
Table 2 Relative change from baseline in the levels of cardiovascular biomarkers and fasting lipids
Biomarker (units) ABC/3TC arm, % (IQR) TDF/FTC arm, % (IQR) P values
D-dimer (μg/l)
Week 4 na na na
Week 12 9 (-10-44) 8 (-17-29) 0.770
Week 48 1 (-24-40) 22 (-9-47) 0.301
hs-CRP (mg/l)
Week 4 41 (-32-82) -27 (-50-59) 0.378
Week 12 32 (-36-106) -9 (-46-44) 0.279
Week 48 23 (-44-120) -27 (-59- [-]2) 0.110
IL-6 (pg/ml)
Week 4 0 (-33-6) 0 (-22-88) 0.555
Week 12 0 (-15-58) 0 (-15-38) 0.883
Week 48 0 (-15-39) 0 (-25-29) 0.673
E-selectin (ng/ml)
Week 4 14 (-1-31) -7 (-28-3) 0.004
Week 12 19 (-2-56) 6 (-11-20) 0.152
Week 48 19 (-1-36) 6 (-11-21) 0.162
sVCAM-1 (ng/ml)
Week 4 8 (-10-15) -11 (-24-4) 0.041
Week 12 17 (-11-59) 6 (-19-17) 0.198
Week 48 2 (-12-16) -3 (-15-12) 0.739
sICAM-1 (ng/ml)
Week 4 -1 (-9-10) -10 (-26-3) 0.061
Week 12 8 (-6-53) 9 (-8-21) 0.501
Week 48 0 (-18-15) -3 (-12-13) 0.973
MPO (ng/ml)
Week 4 77 (0-508) 31 (-9-821) 0.793
Week 12 51 (4-264) 67 (30-214) 0.726
Week 48 25 (-30-128) 11 (-78-71) 1.000
Total cholesterol (mmol/l)
Week 12 4 (-2-13) -3 (-11-0) 0.020
Week 48 11 (4-19) -10 (-13-1) 0.002
LDL (mmol/l)
Week 12 0 (-9-6) -4 (-13-15) 0.640
Week 48 4 (-5-14) -12 (-18-17) 0.117
HDL (mmol/l)
Week 12 6 (-8-20) 0 (-19-0) 0.059
Week 48 23 (10-30) 0 (-9-9) 0.002
Triglycerides (mmol/l)
Week 12 27 (-14-50) -8 (-21-18) 0.065
Week 48 20 (-14-90) 0 (-25-12) 0.121
Total cholesterol/HDL ratio
Week 12 2 (-15-16) 1 (-7-10) 0.872
Week 48 -6 (-16-3) -4 (-20-8) 0.894
Hs-CRP = high sensitivity C-reactive protein; IL-6 = interleukin 6; sVCAM-1 = soluble vascular adhesion molecule-1; slCAM-1 = soluble intercellular adhesion
molecule-1; MPO = myeloperoxidase; LDL = low density lipoprotein; HDL = high density lipoprotein; na = not available.
Relative change (%) from baseline in the levels of cardiovascular biomarkers and fasting lipids according to study arm for each biomarker; comparison across
study arms performed by Wilcoxon rank sum test. Applying Bonferroni’s correction for multiple testing would yield a significance level of 0.002 to be used in the
statistical evaluation of all variables.
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Page 7 of 10rule out that the statistical phenomenon of regression
towards the mean is contributing to the relative increase
of these two biomarkers in the ABC/3TC arm compared
with the TDF/FTC arm from baseline to week 4.
Both E-selectin and sVCAM-1 are associated with ather-
osclerosis, risk of cardiovascular events, and risk of death
in patients with known cardiovascular disease [26-29]
even though these associations have not yet been proven
in HIV-infected patients. The association of ABC use and
risk of MI in the DAD study data was no longer present 6
months after stopping ABC [1], but the temporal beha-
viour of the risk within this period is unknown. Our data
suggest that the effect on vascular inflammation is fast act-
ing, short-lived, and that no continuous pro-inflammatory
effect is present. This could be relevant when considering
switching treatment from ABC in patients with low cardi-
ovascular risk who have been on ABC for several years.
Such patients may not benefit from a therapy change with
respect to cardiovascular risk.
Hs-CRP is a well-established marker of risk prediction of
coronary events [14,15,23] and contains prognostic infor-
mation with a cut-off as low as 1 mg/L. In a post hoc ana-
lysis, we tested for differences in the proportion of patients
with hs-CRP above this limit. However, even though the
proportion of patients with hs-CRP > 1 mg/L, as well as
overall levels of hs-CRP, seemed to decrease with TDF/
FTC treatment as compared with ABC/3TC treatment,
the differences were not significant. Because of the low
prevalence of detectable plasma HIV-RNA in our samples,
any decrease in inflammatory markers is unlikely to be
caused by improved virological control. We have recently
shown that TDF down-regulates production of pro-
inflammatory cytokines following stimulation of mono-
cytes with lipopolysaccheride [30], and we speculate that
TDF may have inherent anti-inflammatory properties that
affect both upstream and downstream inflammatory mar-
kers to a modest degree.
Our study is limited by the small number of patients,
which reduces the statistical power to detect differences
between groups. Furthermore, the large number of com-
parisons made increases the likelihood that significant
findings could have arisen by chance alone. However,
the observed transient increases in biologically related
endothelial biomarkers, including a tendency towards a
similar transient increase in sICAM-1, speak against this
possibility. All 5 participants who were excluded from
the study (2 after baseline and 3 after week 12 measure-
ments) were in the ABC/3TC arm, introducing a poten-
tial source of bias. However, in only one of these
patients, who had pre-existing diabetes, was the reason
for exclusion related to metabolic or cardiovascular
causes. This was a sub-study that was not planned in
the original protocol, but collection of plasma samples
and lipid measurements were already established, and
further selection of patients was not necessary. In the
case of IL-6 measurements, 55% of samples had unde-
tectable levels and were assigned the value of the lower
detection limit to allow for statistical analyses; these
assigned values may not reflect the true IL-6
concentration.
Conclusion
In conclusion, levels of total cholesterol and high-den-
sity lipoprotein (HDL) increased relatively during
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Figure 3 Proportion with hs-CRP > 1 mg/L according to study arm. The proportion of patients with hs-CRP > 1 mg/L is shown for each
treatment arm at the various time points. At each time point, the two study arms are compared using c
2;-test; corresponding P-values are
indicated above the graphs. Hs-CRP = high sensitivity C-reactive protein.
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Page 8 of 10treatment with ABC/3TC compared with TDF/FTC, but
no difference was found in total cholesterol/HDL ratio.
We observed transient increases in the plasma levels of
E-selectin and sVCAM-1 in patients randomized to
ABC/3TC compared with TDF/FTC, but no difference
was found in other biomarkers associated with endothe-
lial dysfunction, inflammation, or coagulation. The clini-
cal significance of these findings is uncertain.
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